Liquidia Loses Bid to Grease Yutrepia Drug Approval Amid Appeal

Liquidia Corp. failed to partially block a Delaware federal court’s enforcement of a judgment that would block regulatory approval of Yutrepia, its treatment for high blood pressure in the lungs, until 2027, when a patent for United Therapeutics Corp.’s rival Tyvaso—deemed valid and infringed by a district court but separately voided by an administrative tribunal—is set to expire.

Liquidia had sought the denied stay from District Judge Richard G. Andrews of that provision in his August 2022 judgment pending UTC’s Federal Circuit appeal of the Patent Trial and Appeal Board’s second cancellation of US Patent No. 10,716,793. The patent ...